nn_logo_cmyk_blue_small.jpg
Status re Novo Nordisk's holding of its own shares
July 12, 2000 06:00 ET | Novo Nordisk A/S
In continuation of the company's announcement on 3 November 1999 of a planned stock repurchasing programme, and pursuant to Section 204.33, Treasury Stock Changes, of the New York Stock Exchange...
nn_logo_cmyk_blue_small.jpg
Status re Novo Nordisk's holding of its own sharesand announcement of an extension of the existing programme
July 03, 2000 06:00 ET | Novo Nordisk A/S
In continuation of the company's announcement on 3 November 1999 of a planned stock repurchasing programme of up to DKK 2 billion, and pursuant to Section 204.33, Treasury Stock Changes, of the New...
nn_logo_cmyk_blue_small.jpg
Roche and Novo Nordisk agree on a worldwide strategic alliance for feed enzymes
June 30, 2000 06:00 ET | Novo Nordisk A/S
Basel, Switzerland / Bagsværd, Denmark: Roche and Novo Nordisk A/S (NYSE:NVO) have agreed on a worldwide strategic alliance in the area of feed enzymes. The objective of the strategic alliance...
nn_logo_cmyk_blue_small.jpg
Roche and Novo Nordisk agree on a worldwide strategic alliance for feed enzymes
June 30, 2000 06:00 ET | Novo Nordisk A/S
The objective of the strategic alliance between Roche's Vitamins and Fine Chemicals Division and Novo Nordisk's Enzyme Business is to support growth by pioneering and driving the development of new...
nn_logo_cmyk_blue_small.jpg
US Food and Drug Administration approves liquid Norditropin®
June 21, 2000 06:00 ET | Novo Nordisk A/S
First and only premixed growth hormone with dedicated delivery system   Novo Nordisk A/S (NYSE: NVO) announced today that the United States Food and Drug Administration (FDA) has approved its...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk and American Home Products settle patent dispute
June 16, 2000 06:00 ET | Novo Nordisk A/S
Under the agreement, Novo Nordisk and Pharmacia Corporation will take a licence under American Home Products patent rights with respect to Activella(TM) (oestradiol/norethindrone acetate tablets)....
nn_logo_cmyk_blue_small.jpg
The demerger of Novo Nordisk moving one step closer
June 14, 2000 06:00 ET | Novo Nordisk A/S
The documents in question comprise a demerger plan including the directors' report, articles of association for both companies, joint statement of account and proposals for opening balance sheets...
nn_logo_cmyk_blue_small.jpg
FDA approves NovoLog®, new rapid-acting Insulin analogue from Novo Nordisk
June 08, 2000 06:00 ET | Novo Nordisk A/S
NovoLog® has faster absorption, faster onset of action and shorter duration of action than regular human insulin. The quick onset of blood sugar lowering after injection of NovoLog® allows people...
nn_logo_cmyk_blue_small.jpg
New members appointed to ZymoGenetics' Board of Directors
May 30, 2000 06:00 ET | Novo Nordisk A/S
George B Rathmann, founder and previously CEO and chairman of Amgen and subsequently ICOS Corporation, is the current president and CEO of Hyseq, Inc.   Edward E Penhoet, founder and former...
nn_logo_cmyk_blue_small.jpg
Financial statement for the first quarter of 2000
May 03, 2000 06:00 ET | Novo Nordisk A/S
  Consolidated sales increased 20% to DKK 5,564 million. Measured in local currencies, sales increased 11%. - Health Care sales up 23%.   - Enzyme Business sales up 8%. Operating...